Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Information Request Regarding pH of Smokeless Tobacco Products, 64394-64397 [2014-25638]
Download as PDF
64394
Federal Register / Vol. 79, No. 209 / Wednesday, October 29, 2014 / Notices
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1—Continued
Number of
recordkeepers
21 CFR section
Number of
records per
recordkeeper
Total annual
records
Average
burden per
recordkeeping
Total hours
600.80(c)(1) and 600.80(i) ...................................................
131
1,718.60
225,137
1
225,137
Total ..............................................................................
........................
........................
........................
........................
485,817
1 There
2 The
are no capital costs or operating and maintenance costs associated with this collection of information.
recordkeeping requirements in § 610.18(b) are included in the estimate for § 600.12.
Dated: October 23, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2014–25637 Filed 10–28–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–1009]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Information
Request Regarding pH of Smokeless
Tobacco Products
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by November
28, 2014.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–NEW and
title ‘‘Information Request Regarding pH
of Smokeless Tobacco Products.’’ Also
include the FDA docket number found
in brackets in the heading of this
document.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
VerDate Sep<11>2014
16:21 Oct 28, 2014
Jkt 235001
Information Request Regarding pH of
Smokeless Tobacco Products—(OMB
Control Number 0910–NEW)
On June 22, 2009, President Obama
signed the Family Smoking Prevention
and Tobacco Control Act (the Tobacco
Control Act) (Pub. L. 111–31) into law.
The Tobacco Control Act amended the
Federal Food, Drug, and Cosmetic Act
(the FD&C Act) by granting FDA
authority to regulate the manufacture,
marketing, and distribution of tobacco
products to protect the public health
generally and to reduce tobacco use by
minors.
Section 904(b) of the FD&C Act (21
U.S.C. 387d(b)) states that at the request
of the Secretary, each tobacco product
manufacturer or importer, or agents
thereof, must submit:
• Any or all documents (including
underlying scientific information)
relating to research activities, and
research findings, conducted,
supported, or possessed by the
manufacturer (or agents thereof) on the
health, toxicological, behavioral, or
physiological effects of tobacco products
and their constituents (including smoke
constituents), ingredients, components,
and additives.
• Any or all documents (including
underlying scientific or financial
information) relating to research
activities, and research findings,
conducted, supported, or possessed by
the manufacturer (or agents thereof) that
relate to the issue of whether a
reduction in risk to health from tobacco
products can occur upon the
employment of technology available or
known to the manufacturer.
• Any or all documents (including
underlying scientific or financial
information) relating to marketing
research involving the use of tobacco
products or marketing practices and the
effectiveness of such practices used by
tobacco manufacturers and distributors.
If the Secretary requests information
from the manufacturer of a tobacco
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
product not manufactured in the United
States, the importer of the tobacco
product is required to supply the
information. FDA is requesting OMB
approval of an information collection
under section 904(b) of the FD&C Act.
To become better informed about the
impact of the use of tobacco products on
the public health, FDA would request
information about the effects of product
pH in smokeless tobacco products from
all tobacco product manufacturers. FDA
would send letters to tobacco product
manufacturers and importers who FDA
has identified as having an obligation to
respond based on information before the
Agency. The requested information
would include information about
research requested under section 904(b)
of the FD&C Act as well as information
to be provided voluntarily beyond the
inquiries described in section 904(b).
I. Information Requested
The proposed request would include
the following information:
All documents (including underlying
scientific information and financial
information) relating to research
activities and research findings
conducted, supported, or possessed by
the respondent or the respondent’s
agents relating to a specified set of
topics listed in this document. The
request includes but is not limited to
documents relating to research findings
and activities, if any, that the
respondent possesses as the result of
acquiring or merging with another
company. For purposes of the request,
‘‘research’’ would include, but would
not be limited to, focus groups, surveys,
experimental clinical studies,
toxicological and biochemical assays, in
vivo and in vitro assays including
animal testing, laboratory formulation
and processing testing, taste panels, and
assessments of the effectiveness of
product marketing practices. The
request would apply to research relating
to any and all smokeless tobacco
products, including but not limited to
those products for research,
investigational use, developmental
studies, test marketing, and/or
commercial marketing, and also to the
E:\FR\FM\29OCN1.SGM
29OCN1
Federal Register / Vol. 79, No. 209 / Wednesday, October 29, 2014 / Notices
components, parts, or accessories of
such products. For products not
manufactured in the United States, the
request would apply to the extent the
respondent has imported such products
into the United States.
II. Topics
Under section 904(b) of the FD&C Act,
FDA would request all documents and
underlying scientific and financial
information relating to research
activities, research findings, and
marketing research for smokeless
tobacco products developed since
January 1, 1980, on the following topics:
• The effect of product pH on ratio of
free/bound (unprotonated/protonated)
nicotine;
• the effect of product pH on user
behavior;
• the effect of product pH on user
subjective effects and experiences
including, but not limited to, sensory
effects in the mouth and throat, liking,
craving and withdrawal symptoms,
stimulation, concentration, and anxiety;
• the effect of product pH on user
physiological responses including, but
not limited to, heart rate, blood
pressure, temperature, and nicotine
pharmacokinetics; and
• for smokeless tobacco products that
have a pH of 7.2 or less, marketing
research that includes attractiveness or
appeal to new users, inexperienced
users, and/or to persons under the age
of 25.
Research and development of
methodology for adjusting the pH of
smokeless tobacco products would be
specifically excluded from this 904(b)
request.
mstockstill on DSK4VPTVN1PROD with NOTICES
III. Limitations on Types of Documents
and Information
With respect to the topics listed, FDA
would request only the following
documents and information:
• Study proposals, original
implemented protocols (including all
amendments), analysis plans,
agreements, notebooks, data collection
tools, including but not limited to,
forms and assessment scales for
planned, ongoing, or completed studies,
surveys, and other research, whether for
external release or internal use;
• final data analyses and reports
regarding studies, surveys, data
compilations, or other research, whether
for external or internal use (if there were
no final analyses, interim data analyses
would be included in the request);
• posters and/or presentations
exhibited or to be exhibited at external
meetings or conferences if the
underlying data has not been presented
VerDate Sep<11>2014
16:21 Oct 28, 2014
Jkt 235001
in other documents and information
within the request;
• manuscripts, articles, editorials,
and letters that have been submitted for
publication but not yet published (e.g.,
in review, accepted, rejected); and
• underlying data (e.g., in the form of
spreadsheets, datasets, charts, tables,
and diagrams) analyzed to produce any
of the data analyses, reports, posters,
manuscripts, or articles requested
previously in this notice.
FDA would request only the final
versions of documents, or in the absence
of a final version, the most recent draft
of each document. Published (i.e.,
publically available) press releases,
abstracts, editorials, letters,
manuscripts, material safety data sheets,
and Department of Health and Human
Services correspondences, would not be
requested, although FDA would
appreciate a list of such publications
provided as a separate appendix. Data
supporting summary reports would be
included in the request, and FDA would
ask that spreadsheets or datasets be
submitted both in PDF and in a file type
and structured format that allows for
meaningful review and analysis of the
data (e.g., Excel (.xls), comma separated
values (.csv), or SAS transport (.xpt) file
formats). Also, FDA would request
relevant data submissions be
accompanied by the name and version
of the software used to create the file,
and names and definitions of variables
and copies of programs and macros
needed to generate the analyses. FDA
would also ask that respondents include
any data analyses that stratify scientific
results by gender, race, ethnicity, age, or
other similar factors.
To provide context and background
for each document, FDA would ask the
respondent to include a load file
containing metadata (e.g., manufacturer,
date, author(s)) for each document. Also
in the metadata load file, FDA would
ask the respondents to identify the
presence of each document in the
University of California San Francisco
Legacy Tobacco Documents Library
(LTDL) as one of the following: Present
with the Bates number (begin Bates
number to end Bates number), not
present, or unknown.
As an option, information responsive
to the request that has been previously
provided to FDA under sections
904(a)(1), 904(a)(3), 904(c)(1), 904(c)(2),
or 904(c)(3) of the FD&C Act would not
have to be resubmitted as long as the
document was fully referenced in the
metadata load file.
IV. Additional Information
FDA would ask the respondent to
submit voluntarily the following
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
64395
additional information, as applicable, to
provide context and background for
FDA:
• A summary (one to five pages in
length) for each of the topics previously
mentioned in this notice, that includes
the number and type of documents
included, and a high level overview of
the content; and
• an explanation of the scientific and
business reasons, rationale, or
justification for developing and
marketing smokeless tobacco products
with different pH values, including
expected and observed perception and
behavior of current and potential
consumers.
This is a new collection of
information. FDA would use the
information to assess the effects of pH
of smokeless tobacco products on
consumers and the public health. In the
Federal Register of July 23, 2014 (79 FR
42797), FDA published a 60-day notice
requesting public comment on the
proposed collection of information.
Four commenters submitted nine
comments that were PRA related.
(Comment 1) The Agency should
request all document versions,
including drafts, as well as comments
on those versions and reasons for
changes made in subsequent versions.
(Response) FDA believes the request
to prepare a submission that includes
drafts including related metadata will be
overly burdensome for the respondent.
Additionally, a request to be provided
the reason for changes made in
subsequent versions is beyond the
inquiries described in section 904(b).
FDA clarified the request to note the
original implemented protocol is to be
submitted. FDA would contact
manufacturers, if additional information
is needed to facilitate the Agency’s
review of the submission.
(Comment 2) Do not limit the request
to SAS datasets as to not exclude other
statistical software.
(Response) It is FDA’s intent that data
not be excluded from the request based
upon the statistical analysis software
used. The proposed request asks that
data be provided in a file type and
structured format that allows for
meaningful review and analysis of the
data. The request was clarified to note
that SAS.xpt is a recommended format
for datasets.
(Comment 3) The Agency should
request the LTDL tobacco identification
(TID) number or URL since these are
unique to the document.
(Response) Because the manufacturer
does not assign the TID number or URL,
FDA believes requesting this
information would be overly
burdensome for the respondent and
E:\FR\FM\29OCN1.SGM
29OCN1
64396
Federal Register / Vol. 79, No. 209 / Wednesday, October 29, 2014 / Notices
therefore would request only the Bates
number(s) as proposed, given that this
information is assigned by the
manufacturer.
(Comment 4) It would be overly
burdensome for the respondent to locate
data and provide the requested software
for information dating back to January 1,
1970, and FDA should focus the
information for more recent times.
(Response) FDA believes the time
period for this request should coincide
with the commercial availability of
smokeless tobacco products with
different pH values because industry
research on this topic is limited in the
public domain. FDA has considered the
scientific value of the data and
information as well as the burden on
respondents to provide such
information to FDA. Therefore, FDA
revised the request to ask for documents
developed since January 1, 1980.
(Comment 5) The burden for the
collection was underestimated given
that it is likely older documents may
only exist in hard copy and, if found,
would be in remote storage that would
be mostly searched manually.
(Response) The burden was revised
given that this portion of the request
may be performed manually.
(Comment 6) The burden for the
collection was underestimated given
that respondents would need to perform
document-by-document search of a
third party site to provide the requested
metadata from LTDL.
(Response) The burden was revised
given that this portion of the request
may be performed manually.
(Comment 7) It would be overly
burdensome for respondents to provide
the amount of metadata requested for
documents previously submitted to FDA
in lieu of providing the Agency with all
of the responsive documents it locates.
(Response) FDA clarified the purpose
of the metadata load file and also
clarified that the respondent has the
option to provide metadata for
previously submitted documents.
(Comment 8) It would take at least 90
days to provide a response to the
request.
(Response) Given the Agency’s
experience with previous submissions
under section 904(a)(4) and 904(b) of the
FD&C Act, FDA would request a
response within 60 days from the date
of the letter and request respondents
that anticipate difficulties with the
document production to contact FDA
within 30 days of the date of the letter.
FDA will provide assistance in resolving
any technical difficulties and facilitate
compliance with the timeline.
(Comment 9) The Agency previously
estimated an average of 200 hours per
response for the Agency’s request for
dissolvable tobacco products in 2011.
(Response) FDA has since learned
from experience with document
submissions under section 904(a)(4) and
904(b) of the FD&C Act that some
respondents have electronic document
systems. Thus, estimates for this
collection reflect automation
capabilities for processing and
managing document submissions.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Type of respondent gathering
product pH information
Tobacco product manufacturers and importers with LTDL collections ...............
Additional tobacco product manufacturers and importers with previous submissions to FDA ...................................
Other manufacturers who have no documents, do not manufacture smokeless
tobacco products, or do not anticipate
manufacturing these products ..............
Total ..................................................
mstockstill on DSK4VPTVN1PROD with NOTICES
1 There
Number of
responses per
respondent
Number of
respondents
Average
burden hours
per response
Total annual
responses
Total hours
Total capital
costs
3
1
3
165
495
$29
3
1
3
175
525
186
119
1
119
5
595
59
........................
........................
........................
........................
1,615
274
are no operating and maintenance costs associated with this collection of information.
We estimate the capital costs
associated with this document to be
$274. This estimate is based upon: (1) 3
Submissions being submitted by mailing
an average of 10 CDs per envelope ($29),
(2) 3 submissions being submitted by
mailing a package of paper documents
weighing an average of 50 pounds total
($186), and (3) 119 submissions of 1
business class letter describing that no
documents are available (119 × $0.49
(the price of a first class business
stamp), or $59).
FDA is drawing from tobacco health
document submissions under section
904(a)(4) and 904(b) of the FD&C Act,
our interaction with the public, and our
experience to inform the burden
estimates associated with this
information collection. Additionally,
based upon comments in response to
VerDate Sep<11>2014
16:21 Oct 28, 2014
Jkt 235001
the Federal Register notice, FDA is
revising its initial estimates of
annualized burden hours.
FDA estimates the burden for this
collection of information to be 1,615
hours. FDA estimates it will receive 125
submissions. Based upon the expected
number of tobacco product
manufacturers and importers, their
burden has been broken into three tiers:
• FDA anticipates documents for this
request will be submitted by three
tobacco product manufacturers and
importers that have document
collections within LTDL. Manufacturers
one through three were estimated to
take 201, 206, and 85 hours
respectively, for an approximate average
of 165 hours per response, to process
and prepare a submission (i.e., cover
letter, documents and information, and
metadata load file). Total burden hours
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
for this portion of the collection are
expected to be 495 hours.
• FDA anticipates documents to also
be submitted by three additional
tobacco product manufacturers and
importers that provided health
documents under section 904(a)(4).
Manufacturers four through six were
estimated to take 304, 118, and 91 hours
respectively, for an approximate average
of 175 hours per response, to process
and prepare a submission (i.e., cover
letter, documents and information, and
metadata load file). Total burden hours
for this portion of the collection are
expected to be 525 hours.
• FDA estimates that 119
manufacturers and importers will not
possess documents responsive to this
request. These manufacturers do not
have documents, do not manufacture
smokeless tobacco products, or do not
E:\FR\FM\29OCN1.SGM
29OCN1
Federal Register / Vol. 79, No. 209 / Wednesday, October 29, 2014 / Notices
anticipate manufacturing these tobacco
products and are estimated to take
approximately 5 hours each to conduct
a review of their records, draft and send
a letter to FDA indicating that they do
not have documents to submit. Total
burden hours for this portion of the
collection are expected to be 595 hours.
ONDEnhancedComm@fda.hhs.gov; or
Stephen Ripley, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301,
Silver Spring, MD 20993–0002, 240–
402–7911.
SUPPLEMENTARY INFORMATION:
Dated: October 23, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
I. Background
One of FDA’s performance
commitments made as part of the fifth
authorization of the Prescription Drug
User Fee Act (PDUFA) under Title I of
the Food and Drug Administration
Safety and Innovation Act (Pub. L. 112–
144), related to promoting innovation
through enhanced communication
between FDA and sponsors during drug
(including biological product)
development, is for FDA to publish draft
guidance for industry and review staff
describing best practices for
communication between FDA and IND
sponsors during drug development. (A
copy of the PDUFA Reauthorization
Performance Goals and Procedures;
Fiscal Years 2013 Through 2017 is
available on the FDA Web site at
https://www.fda.gov/downloads/
forindustry/userfees/
prescriptiondruguserfee/
ucm270412.pdf.)
The guidance will describe FDA’s
philosophy regarding timely interactive
communication with IND sponsors as a
core activity and the scope of
appropriate interactions between the
review team and the sponsor, outline
the types of advice that are appropriate
for sponsors to seek from FDA in
pursuing their drug development
program, describe the general
expectations for the timing of FDA
response to IND sponsor inquiries of
simple and clarifying questions or
referral of more complex questions to
the formal meeting process, and
describe best practices and
communication methods (including the
value of person-to-person scientific
dialogue) to facilitate interactions
between the FDA review team and the
IND sponsor during drug development.
We anticipate that the best practices
will include expectations and agreement
on appropriate methods (e.g., when
teleconferencing or secure email may be
the most appropriate means of
communication) and frequency of such
communications.
[FR Doc. 2014–25638 Filed 10–28–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–1575]
Best Practices for Communication
Between the Food and Drug
Administration and Investigational
New Drug Sponsors During Drug
Development; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice; establishment of docket,
request for comments.
ACTION:
The Food and Drug
Administration (FDA) is announcing the
establishment of a docket to receive
suggestions, recommendations, and
comments from interested parties,
including academic institutions,
regulated industry, and other interested
organizations on best practices for
communication between FDA and
investigational new drug application
(IND) sponsors during drug
development. These comments will
help FDA identify and ultimately
establish best practices to be included in
a draft guidance for industry and review
staff.
DATES: Submit either electronic or
written comments by December 29,
2014.
ADDRESSES: Submit electronic
comments to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. Identify
comments with the docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Rachel E. Hartford, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 6312,
Silver Spring, MD 20993–0002, 301–
796–0331, email:
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:21 Oct 28, 2014
Jkt 235001
II. Establishment of a Docket and
Request for Comments
To help FDA identify and ultimately
establish best practices to be included in
a draft guidance, FDA is requesting
public suggestions, recommendations,
and comments for each aspect of the
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
64397
best practices mentioned above. FDA
will consider all comments submitted.
FDA generally will not respond directly
to the person or organization submitting
the comment.
III. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: October 22, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–25641 Filed 10–28–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Inspector General
Solicitation of Information and
Recommendations for Revising OIG’s
Non-Binding Criteria for Implementing
Permissive Exclusion Authority Under
Section 1128(b)(7) of the Social
Security Act
Office of Inspector General
(OIG), HHS.
ACTION: Notice; Extension of comment
period.
AGENCY:
This document announces an
extension of the public comment period
for the OIG Federal Register notice
published on July 11, 2014 (79 FR
40114). The notice solicited input from
the public on revising the criteria used
by OIG in implementing its permissive
exclusion authority under Section
1128(b)(7) of the Social Security Act.
Due to a technical problem, the public
may have been unable to submit
comments at https://www.regulations.gov
during the comment period.
Accordingly, we are extending the
comment period to ensure that the
public has an opportunity to provide
input.
DATES: To ensure consideration, public
comments must be delivered to the
address provided below by no later than
5 p.m. on December 29, 2014.
ADDRESSES: In commenting, please refer
to file code OIG–1271–N. Because of
staff and resource limitations, we cannot
SUMMARY:
E:\FR\FM\29OCN1.SGM
29OCN1
Agencies
[Federal Register Volume 79, Number 209 (Wednesday, October 29, 2014)]
[Notices]
[Pages 64394-64397]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-25638]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-1009]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Information Request
Regarding pH of Smokeless Tobacco Products
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
November 28, 2014.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-NEW and
title ``Information Request Regarding pH of Smokeless Tobacco
Products.'' Also include the FDA docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Information Request Regarding pH of Smokeless Tobacco Products--(OMB
Control Number 0910-NEW)
On June 22, 2009, President Obama signed the Family Smoking
Prevention and Tobacco Control Act (the Tobacco Control Act) (Pub. L.
111-31) into law. The Tobacco Control Act amended the Federal Food,
Drug, and Cosmetic Act (the FD&C Act) by granting FDA authority to
regulate the manufacture, marketing, and distribution of tobacco
products to protect the public health generally and to reduce tobacco
use by minors.
Section 904(b) of the FD&C Act (21 U.S.C. 387d(b)) states that at
the request of the Secretary, each tobacco product manufacturer or
importer, or agents thereof, must submit:
Any or all documents (including underlying scientific
information) relating to research activities, and research findings,
conducted, supported, or possessed by the manufacturer (or agents
thereof) on the health, toxicological, behavioral, or physiological
effects of tobacco products and their constituents (including smoke
constituents), ingredients, components, and additives.
Any or all documents (including underlying scientific or
financial information) relating to research activities, and research
findings, conducted, supported, or possessed by the manufacturer (or
agents thereof) that relate to the issue of whether a reduction in risk
to health from tobacco products can occur upon the employment of
technology available or known to the manufacturer.
Any or all documents (including underlying scientific or
financial information) relating to marketing research involving the use
of tobacco products or marketing practices and the effectiveness of
such practices used by tobacco manufacturers and distributors.
If the Secretary requests information from the manufacturer of a
tobacco product not manufactured in the United States, the importer of
the tobacco product is required to supply the information. FDA is
requesting OMB approval of an information collection under section
904(b) of the FD&C Act. To become better informed about the impact of
the use of tobacco products on the public health, FDA would request
information about the effects of product pH in smokeless tobacco
products from all tobacco product manufacturers. FDA would send letters
to tobacco product manufacturers and importers who FDA has identified
as having an obligation to respond based on information before the
Agency. The requested information would include information about
research requested under section 904(b) of the FD&C Act as well as
information to be provided voluntarily beyond the inquiries described
in section 904(b).
I. Information Requested
The proposed request would include the following information:
All documents (including underlying scientific information and
financial information) relating to research activities and research
findings conducted, supported, or possessed by the respondent or the
respondent's agents relating to a specified set of topics listed in
this document. The request includes but is not limited to documents
relating to research findings and activities, if any, that the
respondent possesses as the result of acquiring or merging with another
company. For purposes of the request, ``research'' would include, but
would not be limited to, focus groups, surveys, experimental clinical
studies, toxicological and biochemical assays, in vivo and in vitro
assays including animal testing, laboratory formulation and processing
testing, taste panels, and assessments of the effectiveness of product
marketing practices. The request would apply to research relating to
any and all smokeless tobacco products, including but not limited to
those products for research, investigational use, developmental
studies, test marketing, and/or commercial marketing, and also to the
[[Page 64395]]
components, parts, or accessories of such products. For products not
manufactured in the United States, the request would apply to the
extent the respondent has imported such products into the United
States.
II. Topics
Under section 904(b) of the FD&C Act, FDA would request all
documents and underlying scientific and financial information relating
to research activities, research findings, and marketing research for
smokeless tobacco products developed since January 1, 1980, on the
following topics:
The effect of product pH on ratio of free/bound
(unprotonated/protonated) nicotine;
the effect of product pH on user behavior;
the effect of product pH on user subjective effects and
experiences including, but not limited to, sensory effects in the mouth
and throat, liking, craving and withdrawal symptoms, stimulation,
concentration, and anxiety;
the effect of product pH on user physiological responses
including, but not limited to, heart rate, blood pressure, temperature,
and nicotine pharmacokinetics; and
for smokeless tobacco products that have a pH of 7.2 or
less, marketing research that includes attractiveness or appeal to new
users, inexperienced users, and/or to persons under the age of 25.
Research and development of methodology for adjusting the pH of
smokeless tobacco products would be specifically excluded from this
904(b) request.
III. Limitations on Types of Documents and Information
With respect to the topics listed, FDA would request only the
following documents and information:
Study proposals, original implemented protocols (including
all amendments), analysis plans, agreements, notebooks, data collection
tools, including but not limited to, forms and assessment scales for
planned, ongoing, or completed studies, surveys, and other research,
whether for external release or internal use;
final data analyses and reports regarding studies,
surveys, data compilations, or other research, whether for external or
internal use (if there were no final analyses, interim data analyses
would be included in the request);
posters and/or presentations exhibited or to be exhibited
at external meetings or conferences if the underlying data has not been
presented in other documents and information within the request;
manuscripts, articles, editorials, and letters that have
been submitted for publication but not yet published (e.g., in review,
accepted, rejected); and
underlying data (e.g., in the form of spreadsheets,
datasets, charts, tables, and diagrams) analyzed to produce any of the
data analyses, reports, posters, manuscripts, or articles requested
previously in this notice.
FDA would request only the final versions of documents, or in the
absence of a final version, the most recent draft of each document.
Published (i.e., publically available) press releases, abstracts,
editorials, letters, manuscripts, material safety data sheets, and
Department of Health and Human Services correspondences, would not be
requested, although FDA would appreciate a list of such publications
provided as a separate appendix. Data supporting summary reports would
be included in the request, and FDA would ask that spreadsheets or
datasets be submitted both in PDF and in a file type and structured
format that allows for meaningful review and analysis of the data
(e.g., Excel (.xls), comma separated values (.csv), or SAS transport
(.xpt) file formats). Also, FDA would request relevant data submissions
be accompanied by the name and version of the software used to create
the file, and names and definitions of variables and copies of programs
and macros needed to generate the analyses. FDA would also ask that
respondents include any data analyses that stratify scientific results
by gender, race, ethnicity, age, or other similar factors.
To provide context and background for each document, FDA would ask
the respondent to include a load file containing metadata (e.g.,
manufacturer, date, author(s)) for each document. Also in the metadata
load file, FDA would ask the respondents to identify the presence of
each document in the University of California San Francisco Legacy
Tobacco Documents Library (LTDL) as one of the following: Present with
the Bates number (begin Bates number to end Bates number), not present,
or unknown.
As an option, information responsive to the request that has been
previously provided to FDA under sections 904(a)(1), 904(a)(3),
904(c)(1), 904(c)(2), or 904(c)(3) of the FD&C Act would not have to be
resubmitted as long as the document was fully referenced in the
metadata load file.
IV. Additional Information
FDA would ask the respondent to submit voluntarily the following
additional information, as applicable, to provide context and
background for FDA:
A summary (one to five pages in length) for each of the
topics previously mentioned in this notice, that includes the number
and type of documents included, and a high level overview of the
content; and
an explanation of the scientific and business reasons,
rationale, or justification for developing and marketing smokeless
tobacco products with different pH values, including expected and
observed perception and behavior of current and potential consumers.
This is a new collection of information. FDA would use the
information to assess the effects of pH of smokeless tobacco products
on consumers and the public health. In the Federal Register of July 23,
2014 (79 FR 42797), FDA published a 60-day notice requesting public
comment on the proposed collection of information. Four commenters
submitted nine comments that were PRA related.
(Comment 1) The Agency should request all document versions,
including drafts, as well as comments on those versions and reasons for
changes made in subsequent versions.
(Response) FDA believes the request to prepare a submission that
includes drafts including related metadata will be overly burdensome
for the respondent. Additionally, a request to be provided the reason
for changes made in subsequent versions is beyond the inquiries
described in section 904(b). FDA clarified the request to note the
original implemented protocol is to be submitted. FDA would contact
manufacturers, if additional information is needed to facilitate the
Agency's review of the submission.
(Comment 2) Do not limit the request to SAS datasets as to not
exclude other statistical software.
(Response) It is FDA's intent that data not be excluded from the
request based upon the statistical analysis software used. The proposed
request asks that data be provided in a file type and structured format
that allows for meaningful review and analysis of the data. The request
was clarified to note that SAS.xpt is a recommended format for
datasets.
(Comment 3) The Agency should request the LTDL tobacco
identification (TID) number or URL since these are unique to the
document.
(Response) Because the manufacturer does not assign the TID number
or URL, FDA believes requesting this information would be overly
burdensome for the respondent and
[[Page 64396]]
therefore would request only the Bates number(s) as proposed, given
that this information is assigned by the manufacturer.
(Comment 4) It would be overly burdensome for the respondent to
locate data and provide the requested software for information dating
back to January 1, 1970, and FDA should focus the information for more
recent times.
(Response) FDA believes the time period for this request should
coincide with the commercial availability of smokeless tobacco products
with different pH values because industry research on this topic is
limited in the public domain. FDA has considered the scientific value
of the data and information as well as the burden on respondents to
provide such information to FDA. Therefore, FDA revised the request to
ask for documents developed since January 1, 1980.
(Comment 5) The burden for the collection was underestimated given
that it is likely older documents may only exist in hard copy and, if
found, would be in remote storage that would be mostly searched
manually.
(Response) The burden was revised given that this portion of the
request may be performed manually.
(Comment 6) The burden for the collection was underestimated given
that respondents would need to perform document-by-document search of a
third party site to provide the requested metadata from LTDL.
(Response) The burden was revised given that this portion of the
request may be performed manually.
(Comment 7) It would be overly burdensome for respondents to
provide the amount of metadata requested for documents previously
submitted to FDA in lieu of providing the Agency with all of the
responsive documents it locates.
(Response) FDA clarified the purpose of the metadata load file and
also clarified that the respondent has the option to provide metadata
for previously submitted documents.
(Comment 8) It would take at least 90 days to provide a response to
the request.
(Response) Given the Agency's experience with previous submissions
under section 904(a)(4) and 904(b) of the FD&C Act, FDA would request a
response within 60 days from the date of the letter and request
respondents that anticipate difficulties with the document production
to contact FDA within 30 days of the date of the letter. FDA will
provide assistance in resolving any technical difficulties and
facilitate compliance with the timeline.
(Comment 9) The Agency previously estimated an average of 200 hours
per response for the Agency's request for dissolvable tobacco products
in 2011.
(Response) FDA has since learned from experience with document
submissions under section 904(a)(4) and 904(b) of the FD&C Act that
some respondents have electronic document systems. Thus, estimates for
this collection reflect automation capabilities for processing and
managing document submissions.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Average
Type of respondent gathering product pH information Number of responses per Total annual burden hours Total hours Total capital
respondents respondent responses per response costs
--------------------------------------------------------------------------------------------------------------------------------------------------------
Tobacco product manufacturers and importers with LTDL 3 1 3 165 495 $29
collections............................................
Additional tobacco product manufacturers and importers 3 1 3 175 525 186
with previous submissions to FDA.......................
Other manufacturers who have no documents, do not 119 1 119 5 595 59
manufacture smokeless tobacco products, or do not
anticipate manufacturing these products................
-----------------------------------------------------------------------------------------------
Total............................................... .............. .............. .............. .............. 1,615 274
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no operating and maintenance costs associated with this collection of information.
We estimate the capital costs associated with this document to be
$274. This estimate is based upon: (1) 3 Submissions being submitted by
mailing an average of 10 CDs per envelope ($29), (2) 3 submissions
being submitted by mailing a package of paper documents weighing an
average of 50 pounds total ($186), and (3) 119 submissions of 1
business class letter describing that no documents are available (119 x
$0.49 (the price of a first class business stamp), or $59).
FDA is drawing from tobacco health document submissions under
section 904(a)(4) and 904(b) of the FD&C Act, our interaction with the
public, and our experience to inform the burden estimates associated
with this information collection. Additionally, based upon comments in
response to the Federal Register notice, FDA is revising its initial
estimates of annualized burden hours.
FDA estimates the burden for this collection of information to be
1,615 hours. FDA estimates it will receive 125 submissions. Based upon
the expected number of tobacco product manufacturers and importers,
their burden has been broken into three tiers:
FDA anticipates documents for this request will be
submitted by three tobacco product manufacturers and importers that
have document collections within LTDL. Manufacturers one through three
were estimated to take 201, 206, and 85 hours respectively, for an
approximate average of 165 hours per response, to process and prepare a
submission (i.e., cover letter, documents and information, and metadata
load file). Total burden hours for this portion of the collection are
expected to be 495 hours.
FDA anticipates documents to also be submitted by three
additional tobacco product manufacturers and importers that provided
health documents under section 904(a)(4). Manufacturers four through
six were estimated to take 304, 118, and 91 hours respectively, for an
approximate average of 175 hours per response, to process and prepare a
submission (i.e., cover letter, documents and information, and metadata
load file). Total burden hours for this portion of the collection are
expected to be 525 hours.
FDA estimates that 119 manufacturers and importers will
not possess documents responsive to this request. These manufacturers
do not have documents, do not manufacture smokeless tobacco products,
or do not
[[Page 64397]]
anticipate manufacturing these tobacco products and are estimated to
take approximately 5 hours each to conduct a review of their records,
draft and send a letter to FDA indicating that they do not have
documents to submit. Total burden hours for this portion of the
collection are expected to be 595 hours.
Dated: October 23, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-25638 Filed 10-28-14; 8:45 am]
BILLING CODE 4164-01-P